Latest News
Conference Coverage
Is PASI 100 the new benchmark in psoriasis?
KAUAI, HAWAII – “I think we should just do away with PASI 90 and look at how well our drugs do against the metric of PASI 100.”
Conference Coverage
How to avoid severe diarrhea from apremilast
Delayed up-titration of apremilast is often effective, albeit at cost of slower efficacy.
News
New PsA questionnaire fails to beat existing early screening methods
New eight-item CONTEST questionnaire matched the accuracy of the five-item PEST questionnaire.
Latest News
AbbVie, Samsung Bioepis settle suits with delayed U.S. entry for adalimumab biosimilar
Anti-TNF alpha antibody biosimilar will enter European markets this year, but won’t be in United States until 2023.
Latest News
Dramatic improvements reported after surgery for hidradenitis suppurativa
Many patients said they had significantly lower levels of impairment after surgery, and 27% reported adverse effects.
News
Study using U.K. data quantifies infection risk associated with psoriasis
The most common serious infections were lower respiratory tract, skin and soft tissue, and upper respiratory tract infections.
News
Psoriasis patients often have history of childhood trauma
Improving resilience could be helpful in management of psoriasis.
News
FDA approves certolizumab label update for pregnancy, breastfeeding
Approval is based on data from the CRIB and CRADLE studies.
Latest News
FDA approves IL-23 antagonist for plaque psoriasis
Approval is based on data from two phase 3, identically designed clinical trials, reSURFACE1 and reSURFACE2.
Conference Coverage
PASI responses with biologics similar among white, nonwhite individuals, study finds
MIAMI– Investigators used data from psoriasis studies to determine whether treatment responses differed in skin of color patients.